Olympus Scope Lawsuit

Between 2013 and 2024, contaminated Olympus duodenoscopes infected hundreds of patients at hospitals across the United States. At least 35 people died. The infections were caused by dangerous, drug-resistant bacteria that were extremely difficult to treat. The patients had gone into the hospital for diagnostic or therapeutic procedures involving the bile ducts or pancreas, including gallstone evaluations, pancreatic biopsies, and bile duct imaging. Some came out with infections that damaged organs, required months of intensive care, or proved fatal.

The remarkable part is not simply that it happened. Medical devices fail. Infections occur. What makes the Olympus duodenoscope litigation extraordinary is what plaintiffs allege Olympus knew. Olympus knew its scopes could not be reliably cleaned. Olympus knew that bacteria were surviving the reprocessing process and spreading from patient to patient. Olympus knew that patients were dying. And for years, the company failed to respond with the urgency patient safety required.

This page explains what went wrong, why it went wrong, and the legal options available to patients and families harmed by contaminated Olympus scopes. It is written for people who want to understand not just the claims being filed, but the science, the regulatory failures, and the corporate decisions that turned a solvable engineering problem into a public health catastrophe.

What Is a Duodenoscope?

A duodenoscope is a flexible, lighted tube that physicians thread down a patient’s throat, through the stomach, and into the duodenum, the first section of the small intestine. From there, the scope allows access to the bile ducts, pancreatic duct, and surrounding anatomy. The procedure that uses it is called ERCP, which stands for endoscopic retrograde cholangiopancreatography.

ERCP is one of the most technically demanding procedures in gastroenterology. Our law firm has handled more than our share of medical malpractice lawsuits involving ERCP procedures. The procedure is used to diagnose and treat conditions involving the bile ducts and pancreas, including gallstones lodged in the common bile duct, strictures, tumors, and chronic pancreatitis.

When performed correctly with sterile equipment, ERCP is invaluable. Hundreds of thousands of ERCP procedures are performed in the United States each year. So this is not a niche device used in rare procedures. Olympus dominated a market involving a high volume procedure performed on vulnerable patients.

The duodenoscope differs from a standard endoscope in one critical respect. It has a small mechanical component at its tip called the elevator mechanism. This tiny lever allows the physician to manipulate guidewires, stents, and other instruments during the procedure. Without it, ERCP would not be possible.

The elevator mechanism is also the source of the problem.

The Design Defect: Why These Scopes Cannot Be Reliably Cleaned

The elevator channel is a small enclosed cavity with intricate crevices, seams, and moving parts. It sits at the distal tip of the duodenoscope, the end that contacts the patient’s internal tissue, bile, pancreatic fluid, and blood. After a procedure, this channel is contaminated with biological material. The central question is whether it can be adequately decontaminated before the next patient.

The answer, according to years of outbreak data and peer-reviewed research, is not reliable. Not even when hospitals follow the manufacturer’s cleaning instructions.

Here is why. Standard reprocessing depends on brushes, detergents, and chemical disinfectants reaching every contaminated surface of the device. But the elevator channel is not a smooth, open cavity. It contains tiny gaps between the elevator lever and its housing. It has seals, joints, and moving parts that can trap fluid and debris. The geometry of the channel makes it difficult for brushes and high-level disinfectants to reach every contaminated surface.

Bacteria that survive the cleaning process do not simply sit on the surface waiting to be wiped away. They can form biofilms, which are structured colonies of microorganisms that adhere to surfaces and secrete a protective matrix. Once a biofilm establishes itself inside the elevator channel, it becomes extraordinarily difficult to remove. Standard chemical disinfection may not penetrate the biofilm effectively. The bacteria persist. The next patient who undergoes ERCP with that scope can then be exposed to organisms from a prior patient.

This is not a cleaning failure by hospitals. It is a design failure by Olympus. Plaintiffs allege that the device was engineered in a way that made reliable reprocessing impossible under real world conditions.

Safer Alternative Designs Were Already Available

One of the strongest design defect arguments in the newer Olympus cases is that the company was not trapped by a single engineering option. By the time many later procedures were performed, fully disposable duodenoscopes were already on the market.

That matters because Olympus has long tried to frame the infection risk as an unfortunate byproduct of a necessary reusable device. Plaintiffs push back on that idea by arguing that safer alternatives existed and that Olympus chose not to move aggressively in that direction. Instead, Olympus continued selling reusable or partially reusable scopes that still depended on perfect reprocessing of intricate internal parts, even after years of contamination problems.

This is a major issue with the TJF-Q190V. Olympus promoted that model as an improved design by adding a removable distal endcap. Plaintiffs allege that this was only a partial fix. The device retained the same basic side viewing configuration, elevator mechanism, and internal channels that made complete sterilization difficult. A removable piece at the tip did not eliminate the larger reprocessing problem.

Fully disposable duodenoscopes avoid cross-contamination because they are used once and discarded. That does not automatically prove liability. But it gives plaintiffs a stronger argument that Olympus had a feasible, safer alternative and that the company chose to continue selling designs that kept exposing patients to contamination risk.

CRE, VRE, and Other Drug-Resistant Bacteria

The bacteria most commonly linked to duodenoscope infections belong to a family called Enterobacteriaceae, organisms that normally live in the human gut. The most dangerous strains are those that have developed resistance to carbapenem antibiotics, a class of drugs typically reserved as a last resort for serious infections. These resistant strains are called carbapenem-resistant Enterobacteriaceae, or CRE.

CRE infections are not like ordinary bacterial infections. They often do not respond to most antibiotics. When CRE enters the bloodstream, mortality can approach 50 percent. Patients who survive may endure weeks or months in intensive care, multiple surgeries, organ damage, and long-term medical consequences.

Other drug-resistant organisms have also been linked to contaminated duodenoscopes, including:

• Pseudomonas aeruginosa: a bacterium associated with hospital-acquired pneumonia and bloodstream infections
• Klebsiella pneumoniae: a leading cause of CRE outbreaks in health care settings
• Escherichia coli, or E. coli: strains that can acquire resistance genes and become difficult to treat
• Enterococcus: organisms that can cause bloodstream infections, endocarditis, and other serious infections

These are not exotic pathogens. They are bacteria that exist in hospitals. What makes them deadly is the combination of drug resistance and a delivery mechanism, the contaminated duodenoscope, that can place them directly into the bile ducts and bloodstream of vulnerable patients.

The Olympus Scope Lawsuits Also Include VRE

While CRE outbreaks brought national attention to contaminated duodenoscopes, newer lawsuits make clear that these cases are not limited to a single type of bacteria.

Some recent complaints allege infections involving vancomycin resistant Enterococcus, or VRE, another dangerous drug resistant organism commonly found in hospital settings. Like CRE, VRE is difficult to treat and can cause bloodstream infections, sepsis, and death, especially in already vulnerable patients.

In one recent case, plaintiffs allege that a patient developed VRE bacteremia within days of undergoing an ERCP procedure with an Olympus duodenoscope. The infection progressed rapidly, leading to septic shock, multiple hospitalizations, and ultimately death.

The significance of these allegations is easy for a jury to understand. The Olympus litigation is not frozen in the early outbreak years and is not limited to one class of bacteria. Plaintiffs now contend that contaminated duodenoscopes transmitted a broader range of drug resistant organisms, reinforcing the core claim that the design allowed dangerous pathogens to move from one patient to the next.

What Did Olympus Know, and When Did It Know It?

This is the question at the heart of every duodenoscope lawsuit. The evidence already available creates serious problems for Olympus.

Olympus is a Japanese multinational that dominates the global market for gastrointestinal endoscopes. The company holds a large share of the worldwide market for these devices. In the United States, Olympus duodenoscopes were and remain among the most commonly used devices for ERCP. The scale matters because Olympus was not a small player selling a niche device. It dominated a market involving a high volume procedure performed on hundreds of thousands of patients every year.

Internal documents, FDA communications, and litigation discovery have revealed that Olympus was aware of contamination risks associated with its duodenoscopes long before the major outbreaks became public.

The timeline is powerful. Olympus knew about contamination risks for more than a decade. The company made incremental changes, revised instructions, updated designs, and issued limited recalls or corrections. Plaintiffs allege the fundamental problem persisted. Patients continued to be infected. Patients continued to die.

The Problem Did Not End With the Q180V

For years, Olympus has framed the duodenoscope crisis as a problem tied to older devices, particularly the TJF-Q180V model linked to early CRE outbreaks. The company’s response was to introduce newer designs, including the TJF-Q190V, which included a removable distal endcap intended to improve cleaning.

That narrative is now being challenged by Olympus scope lawsuits around the country.

Plaintiffs allege the Q190V did not solve the core problem. The device still relied on the same basic design features that made earlier duodenoscopes difficult to clean, including the side viewing configuration, the elevator mechanism, and internal channels that can trap biological material. The removable endcap was presented as a solution. Plaintiffs argue that, at best, it was a partial fix.

Regulatory history supports that skepticism. In 2021, Olympus issued an urgent device correction after reports that mucosal tissue could become trapped in the Q190V’s distal endcap. In July 2023, the company issued a Class II recall for the TJF-Q190V following reports of infections and contamination concerns.

That is the key point. This is not just a story about what happened in Seattle in 2013 or Los Angeles in 2015. Plaintiffs now allege that contamination risks persisted into the next generation of Olympus scopes, even after the company had years of data, warnings, and real world outbreaks.

If plaintiffs prove that, it undercuts one of Olympus’s central defenses: that the problem was identified, addressed, and fixed. The newer cases tell a different story.

The FDA’s Role: Regulatory Failure

Olympus bears primary responsibility for the harm caused by its defective devices. But the FDA’s performance in this episode was also a failure.

The agency knew about the risks of duodenoscope contamination as early as 2013. Between 2013 and 2015, the FDA received hundreds of adverse event reports involving duodenoscope related infections. The agency did not act aggressively. It did not order a broad recall. It did not require immediate design changes. It issued safety communications that shifted much of the burden onto hospitals while continuing to allow the devices to be sold.

Part of the problem is structural. Duodenoscopes entered the market through the FDA’s 510(k) clearance pathway, which allows medical devices to be sold without clinical trials if they are substantially equivalent to devices already on the market. The 510(k) process is faster and cheaper than premarket approval, but it does not require the kind of independent clinical proof many patients assume exists.

When safety problems emerged, the FDA had tools available. It could issue warning letters. It could press the company. It could refer cases to the Department of Justice for potential criminal prosecution. What it did not do quickly and decisively was remove the devices from the market or require an immediate engineering solution.

The result was years of preventable infections while the FDA and Olympus engaged in a slow regulatory process.

One of the more troubling features of the Olympus story is that the company’s regulatory problems did not end after the early duodenoscope scandals became public. Even after years of outbreak reports, lawsuits, FDA communications, and public scrutiny, Olympus continued to face safety and quality control problems with other endoscopic devices and related components.

That cuts against the argument that Olympus learned its lesson and cleaned up its act. Plaintiffs can argue that Olympus did not merely mishandle one product line years ago. They can argue that the company continued to show the same core problems with device safety, reprocessing, post-market surveillance, and regulatory compliance long after the duodenoscope crisis should have forced reform.

A jury may view repeated recalls, warning letters, import alerts, and manufacturing problems not as isolated events, but as evidence of a company that kept reacting late, warning late, and fixing problems only after patients had already been harmed.

Why Infection Timing and Culture Results Matter

The strongest Olympus duodenoscope cases usually have a clear medical timeline. A patient undergoes ERCP or another scope procedure, develops fever, sepsis, bacteremia, abscess, cholangitis, or another serious infection within days or weeks, and hospital cultures identify a drug-resistant organism such as CRE, VRE, Pseudomonas, Klebsiella, or another pathogen associated with health care transmission.

That timing matters because Olympus will almost always dispute causation. The defense may argue that the infection came from the patient’s underlying illness, the hospital environment, another procedure, another device, or an unrelated source. Plaintiffs need records that connect the procedure, the scope, the organism, and the infection timeline.

Important evidence includes the ERCP report, scope tracking logs, culture and sensitivity results, infectious disease notes, antibiotic records, ICU records, hospital infection control records, sepsis records, blood cultures, biliary cultures, device reprocessing records, and any notice from the hospital that other patients may have been exposed to the same contaminated device.

Current Status of Olympus Duodenoscope Litigation

Olympus duodenoscope cases are being filed in both federal and state courts across the United States. There is currently no formal multidistrict litigation consolidating all federal cases and no class action lawsuit that controls every victim’s claim. For many victims, that may be a good thing because serious injury and wrongful death cases often need individualized proof of infection timing, culture results, causation, and damages.

The litigation gained renewed momentum in 2025 following FDA import alerts involving Olympus products and the company’s later field safety actions addressing contamination concerns with newer duodenoscope models. These regulatory actions support what plaintiffs have argued for years: Olympus did not fully eliminate the design problem that allows bacteria to survive between patients.

Cases filed in 2024 and 2025 are particularly significant because they involve newer generation scopes that Olympus marketed as safer alternatives to the original TJF-Q180V. If plaintiffs can prove that even the updated designs remained defective, it undermines Olympus’s primary defense that the company identified and corrected the problem years ago.

Discovery in active cases will focus on internal company documents, communications between Olympus and the FDA, hospital infection reports, scope tracking records, engineering assessments of the elevator channel, and the decision making behind later design changes. Those documents will play a central role in upcoming trials and settlement negotiations.

Crux of Olympus Lawsuit Claims

Patients and families harmed by contaminated Olympus duodenoscopes have filed lawsuits in federal and state courts across the country. The claims generally fall into three categories.

1. Design Defect

The core allegation is that Olympus duodenoscopes were defectively designed because their elevator mechanism could not be adequately cleaned using available reprocessing methods. A properly designed reusable device should allow for reliable sterilization between patients. Plaintiffs allege the Olympus scopes did not.

Design defect claims do not always require proof that the manufacturer acted negligently. They require proof that the device was unreasonably dangerous as designed and that a safer alternative design was feasible.

2. Failure to Warn

Olympus knew or should have known that its duodenoscopes posed contamination risks that persisted even when hospitals followed the company’s own reprocessing instructions. The company had a duty to warn physicians, hospitals, and patients of these risks. Plaintiffs allege it failed to do so adequately.

Failure to warn claims are often among the most powerful in medical device litigation because they focus on what the manufacturer knew and when. Internal documents showing that Olympus understood the contamination problem but delayed warnings are central to these claims.

3. Manufacturing Defect

Some claims allege that specific Olympus devices were defectively manufactured, deviating from the company’s design specifications in ways that increased their likelihood of harboring bacteria. The FDA’s findings regarding the Aizu facility support allegations that manufacturing quality control was inadequate.

Who Can File an Olympus Duodenoscope Lawsuit?

If you or a family member underwent an ERCP or another procedure involving an Olympus duodenoscope and subsequently developed a serious infection, you may have a claim. The key questions are:

1. Was an Olympus duodenoscope used during the procedure? Hospital records should document the specific device used. If the records are unclear, the hospital’s risk management or infection control department may be able to confirm.
2. Did you develop an infection within 90 days of the procedure? The most common pattern involves infections that appear within days or weeks after ERCP. Infections requiring hospitalization, IV antibiotics, ICU admission, or surgery are most likely to support a claim.
3. Was the infection caused by a drug resistant organism? Infections involving CRE, VRE, Pseudomonas, Klebsiella, or other resistant bacteria are strongly associated with duodenoscope contamination. Culture results should identify the organism.
4. Did the infection cause significant harm? Patients who died, suffered prolonged hospitalization, required organ transplants, developed kidney failure, or experienced permanent disability have the strongest claims.
5. Is the statute of limitations still open? Each state has its own deadline. The clock may begin when the patient knew or reasonably should have known that the device caused the injury. Because many patients were not told about contamination risks, the discovery rule may matter.

What Compensation Can Victims Recover?

Patients harmed by contaminated Olympus duodenoscopes can seek compensation for:

• Medical expenses: hospital stays, surgeries, medications, rehabilitation, and ongoing care
• Lost wages and earning capacity: income lost during illness and any permanent reduction in the ability to work
• Pain and suffering: physical pain, emotional distress, and diminished quality of life caused by the infection and treatment
• Wrongful death damages: funeral expenses, loss of financial support, loss of companionship, and the suffering the patient endured before death

In cases involving particularly egregious corporate conduct, juries may also award punitive damages. These damages are designed to punish the defendant and deter similar conduct in the future. Evidence that Olympus knew about contamination risks and delayed action could support punitive damages in appropriate cases.

A Patient’s Story: What These Infections Actually Mean

Statistics do not convey what it is like to contract a CRE infection from a routine medical procedure. A patient’s story does.

Consider a 58-year-old woman, a retired schoolteacher and grandmother, who goes into the hospital for evaluation of a suspected gallstone. The procedure is ERCP. It takes less than an hour. She is told she can go home the same day.

Three days later, she develops a fever. Then chills. Then confusion. Her daughter brings her to the emergency room. Blood cultures come back positive for carbapenem-resistant Klebsiella pneumoniae. She is admitted to the ICU.

Over the next six weeks, she undergoes three surgeries. Her bile ducts are infected. Her bloodstream is infected. Her kidneys begin to fail. The infectious disease team cycles through available antibiotics. Nothing works reliably. She develops septic shock twice. Each time, the medical team manages to bring her back.

After two months in the hospital, she is discharged to a rehabilitation facility. She has lost 40 pounds. She cannot walk unassisted. She will need dialysis for the rest of her life because her kidneys never recovered. She went into the hospital for a gallstone. She came out with permanent kidney failure, months of hospitalization, and a drug resistant organism colonizing her body.

This is what the Olympus duodenoscope litigation is about. Not abstract statistics. Not regulatory acronyms. Human beings whose lives were destroyed by a device that the manufacturer allegedly knew was defective.

These Cases Are Extremely Important

Medical device litigation is sometimes criticized as a tax on innovation or a burden on companies trying to develop life saving technologies. That criticism misses the point of cases like this one.

Olympus is not facing lawsuits because medicine is inherently uncertain. Olympus is facing lawsuits because plaintiffs allege the company designed a device that could not be reliably cleaned, learned that patients were dying, and chose to protect its market share rather than fix the problem or warn the people at risk.

Litigation is the accountability mechanism when regulatory agencies fail and when corporations prioritize profits over patient safety. It is how victims obtain compensation for harms inflicted on them through no fault of their own. It is also how the legal system sends a message to every other medical device manufacturer: a company cannot hide what it knows and escape the consequences.

The Olympus duodenoscope cases are not just about the patients who were infected. They are about what kind of system we want. Do we want a system in which companies can sell defective devices, ignore contamination reports, delay warnings, and face no meaningful consequences? Or do we want a system in which corporate knowledge of danger triggers corporate responsibility to act? These lawsuits are one way of answering that question.

Frequently Asked Questions About Olympus Duodenoscope Lawsuits

Olympus Duodenoscope Settlements and Verdicts

Because most Olympus duodenoscope cases have settled under strict confidentiality agreements, publicly available information about settlement amounts is limited. Olympus has been careful to keep financial terms private, likely to avoid establishing benchmarks that could encourage additional claims or increase settlement demands in pending cases.

Regulatory Penalties

In 2016, Olympus Corporation of the Americas agreed to pay $85 million in criminal fines to resolve charges that the company failed to report adverse events to the FDA. This was one of the largest penalties ever imposed in an FDA enforcement action. For plaintiffs, that enforcement history matters because it supports the argument that Olympus had repeated regulatory failures, not isolated mistakes.

Separately, in 2016, Olympus paid $646 million to resolve criminal and civil charges related to an illegal kickback scheme involving its medical devices. While that settlement was not directly about duodenoscope contamination, plaintiffs can argue it fits a broader theme of prioritizing profits over regulatory compliance.

Confidential Individual Settlements

Court filings and legal disclosures indicate that Olympus has settled numerous individual cases involving patients who contracted CRE or other drug resistant infections after ERCP procedures. Settlement amounts remain confidential, but given the severity of injuries in these cases, including deaths, permanent organ damage, prolonged ICU stays, and loss of earning capacity, the amounts are believed to be substantial.

In wrongful death cases, settlements may account for funeral expenses, loss of financial support, loss of companionship, and the pain and suffering the patient experienced before death. In cases involving survivors with permanent injuries, settlements must account for lifetime medical care, lost wages, diminished quality of life, and ongoing treatment for chronic complications.

What Drives Settlement Value

• Severity of injury: Death, permanent organ failure, prolonged disability, or ICU hospitalization generally increase settlement value.
• Age of the victim: Younger patients who lost decades of earning capacity or life expectancy typically have higher damages.
• Strength of causation: Cases where records clearly document the Olympus scope used, timing of infection, and bacterial strain involved are stronger.
• Defendant conduct: Evidence that Olympus knew about contamination risks and delayed warnings can increase punitive damages risk.
• Jurisdiction: Some states cap damages or have more plaintiff friendly juries, which affects settlement negotiations.
• Quality of legal representation: These are complex medical device cases, and experienced counsel can make a meaningful difference.

The lack of publicly reported verdicts means we do not yet have jury determined benchmarks for these cases. That may change if active cases proceed to trial and result in significant plaintiff verdicts.

Contact Us About an Olympus Duodenoscope Claim

If you or a family member developed a serious infection after an ERCP or other procedure involving an Olympus duodenoscope, you may have a claim. Our attorneys handle complex medical device litigation and can evaluate your case at no cost.

Call us at 800-553-8082 or contact us online for a free consultation. We want to hear your story. There is no fee or cost unless we recover compensation for you.